Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 4, 2024
Product Development
Confidence in masked T cell engagers builds with Janux update
Also in BioCentury’s Clinical Report: Cartesian’s autoimmune CAR T durability, Roivant’s miss, Novocure’s pancreatic cancer data, and more
BioCentury | Jul 3, 2024
Product Development
Clinical Report: Updates in myasthenia gravis from J&J, Cartesian
Plus: Readouts for Savara, Lyell and Novo Nordisk
BioCentury | Jun 5, 2023
Product Development
June 5 ASCO Quick Takes: AZ’s Tagrisso impresses with OS data
Plus: Replimune gains on oncolytic virus data in melanoma, and updates from ImmunoGen and Bicara
BioCentury | Jan 7, 2023
Discovery & Translation
Autocrine signaling targets for fibrosis in NASH; plus a blood-based biomarker for Alzheimer’s and more
BioCentury’s roundup of translational news
BioCentury | Nov 18, 2022
Product Development
Oncolytic virus combinations move beyond checkpoint inhibitors
SITC updates suggest the next wave of oncolytic viruses will be paired with bispecifics, cell therapies
BioCentury | Nov 14, 2022
Data Byte
A snapshot of the GM-CSF pipeline
GSK’s decision to drop otilimab brings other GM-CSF therapies under focus
BioCentury | Jul 14, 2022
Finance
July 13 Quick Takes: Pliant raises $200M on back of positive data; CytomX restructuring
Plus ContraFect tumbles on exebacase setback, and updates from AgomAb, Xilis, and more
BioCentury | Jun 17, 2021
Finance
Biden administration commits more than $3B to COVID-19 antiviral development, pandemic preparedness
The Biden administration is allocating more than $3 billion from American Rescue Plan funding towards its Antiviral Program for Pandemics, a collaboration between federal health agencies to support
BioCentury | Jun 5, 2021
Product Development
Fusion proteins lead in TGFβ blockade at ASCO21: Data Byte
Among nine TGFβ-targeting programs with presentations at ASCO21, nearly all have a dual targeting strategy, and five are testing the hypothesis that targeting the immunosuppressive cytokine
BioCentury | Jun 2, 2021
Deals
Royalty deal fuels MorphoSys’ $1.7B Constellation takeout, fattening pipeline behind Monjuvi
Acquisition gives German biotech two clinical cancer assets
Items per page:
1 - 10 of 109